CareDx (CDNA) Tops Q4 EPS by 41c, provides guidance

CareDx (NASDAQ: CDNA) reported Q4 EPS of $0.18, $0.41 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $86.6 million versus the consensus estimate of $82.18 million.

GUIDANCE:

CareDx sees FY2025 revenue of $365-375 million, versus the consensus of $370 million.
CareDx expects full year 2025 adjusted EBITDA gain to be in the range of $29 million to $33 million.

For earnings history and earnings-related data on CareDx (CDNA) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits